Mild Cognitive Impairment

Mild Cognitive Impairment (MCI) beschreibt einen Zustand beobachtbarer und objektivierbarer kognitiver Einschränkungen am Übergang zwischen altersbedingten kognitiven Veränderungen und Demenz. Primär anhand kognitiver Leistungsprofile definiert, bezieht das Syndrom auch die Alltagsrelevanz der kognitiven Einschränkung mit ein. In Gedächtnisambulanzen erhält jede 5. Person die Diagnose MCI [1].

Kernaussagen

• MCI ist eine syndromale Diagnose. Es gibt verschiedene MCI-Definitionen, was zu Unsicherheiten im Umgang mit dem Konstrukt führen kann.

• Über alle Definitionen hinweg ist MCI definiert als Kombination erworbener, beobachtbarer und objektivierbarer Defizite kognitiver Leistungsfähigkeit, die nicht zu deutlichen Einschränkungen in der Bewältigung der Alltagsaktivitäten führen.

• Das Konstrukt sollte vor allem dann verwendet werden, wenn die kognitiven Einschränkungen das klinisch führende Symptom sind.

• Die Diagnose MCI sollte nicht unter alleiniger Nutzung kognitiver Kurztests gestellt werden, sondern i.d.R. nach Durchführung einer ausführlichen neuropsychologischen Untersuchung, die alle relevanten kognitiven Domänen prüft.

• Die diagnostische Abklärung umfasst die Erhebung der Eigen- und Fremdanamnese zu Verlauf und Alltagskompetenz, die klinische Untersuchung und eine vertiefte neuropsychologische Testung.

• Die klinische Relevanz und Aussagekraft des Konstrukts MCI steigt, wenn eine ätiologische Abklärung inkl. der Bestimmung von Biomarkern erfolgt. Hieraus ergeben sich eine Verbesserung der diagnostischen Sicherheit, der prognostischen Wertigkeit und die Grundlage für die Entwicklung effektiver Interventionen.

• Neurodegenerative Erkrankungen, insbesondere auch die Alzheimer-Krankheit, werden aktuell als klinisches Kontinuum verstanden. MCI bezeichnet hier ein Krankheitsstadium, das zwischen subjektiven kognitiven Defiziten und der manifesten Demenz infolge neuropathologischer Veränderungen anzusiedeln ist.

• Die Diagnose MCI hat erhebliche klinische Relevanz, da sich hieraus therapeutische Konsequenzen ableiten.

• Bei MCI treten neben den kognitiven Einschränkungen häufig psychische sowie Verhaltenssymptome auf (z.B. depressive Symptome, Schlafstörungen, Angstzustände).

Schlüsselwörter

Mild Cognitive Impairment - subjektive kognitive Störung - Demenz - Alltagsrelevanz - Biomarker

Publikationsverlauf

Artikel online veröffentlicht:
26. September 2025

• Literatur

• 1 Cook LD, Nichol KE, Isaacs JD. The London memory service audit and quality improvement programme. BJ Psych Bull 2019; 2019: 215-220
• 2 ICD-10-GM Version 2025, Systematisches Verzeichnis, Internationale statistische Klassifikation der Krankheiten und verwandter Gesundheitsprobleme, 10. Revision, Stand: 13.09.2024. Köln: Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM) im Auftrag des Bundesministeriums für Gesundheit (BMG) unter Beteiligung der Arbeitsgruppe ICD des Kuratoriums für Fragen der Klassifikation im Gesundheitswesen (KKG); 2024.
• 3 International Classification of Diseases, Eleventh Revision (ICD-11). World Health Organization (WHO); 2019/2021.
• 4 Association AP. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Washington, DC: American Psychiatric Publishing; 2013
• 5 Casagrande M, Marselli G, Agostini F. et al. The complex burden of determining prevalence rates of mild cognitive impairment: A systematic review. Front Psych 2022; 13: 960648
• 6 Ragusa FS, Veronese N, Vernuccio N. et al. Mild cognitive impairment predicts the onset of sarcopenia: A longitudinal analysis from The English Longitudinal Study on Ageing. Aging Clin Exp Res 2024; 36: 129
• 7 Boccardi M, Handels R, Gold M. et al. Clinical research in dementia: a perspective on implementing innovation. Alzheim Dement 2022; 18: 2352-2367
• 8 Jak AJ, Bondi MW, Delano-Wood L. et al. Quantification of five neuropsychological approaches to defining mild cognitive impairment. Am J Geriatr Psychiatry 2009; 17: 368-375
• 9 Bradfield NI. Mild cognitive impairment: Diagnosis and subtypes. Clin EEG Neurosci 2023; 54: 4-11
• 10 Goodman ZT, Llabre MM, Kaur S. et al. Exploring heterogeneity in mild cognitive impairment. J Alzheimers Dis. 2024; 102: 411-423
• 11 Vassilaki M, Cha RH, Aakre JA. et al. Mortality in mild cognitive impairment varies by subtype, sex, and lifestyle factors: The Mayo Clinic Study of Aging. J Alzheim Dis 2015; 45: 1237-1245
• 12 Thomas KR, Edmonds EC, Eppig JS. et al. MCI-to-normal reversion using neuropsychological criteria in the Alzheimer's Disease Neuroimaging Initiative. Alzheim Dement 2019; 15: 1322-1332
• 13 Damian M, Hausner L, Jekel K. et al. Single-domain amnestic mild cognitive impairment identified by cluster analysis predicts Alzheimer's disease in the European Prospective DESCRIPA Study. Dement Geriatr Cogn Disord 2013; 36: 1-19
• 14 Mitchell A, Shiri-Feshki M. Rate of progression of mild cognitive impairment to dementia – Meta-analysis of 41 robust inception cohort studies. Acta Psy Scand 2009; 119: 252-265
• 15 Koepsell TD, Monsell SE. Reversion from mild cognitive impairment to normal or near-normal cognition: Risk factors and prognosis. Neurology 2012; 79: 1591-1598
• 16 Gao Q, Gwee X, Feng L. et al. Mild cognitive impairment reversion and progression: Rates and predictors in community-living older persons in the Singapore Longitudinal Ageing Studies Cohort. Dement Geriatr Cogn Dis Ex 2018; 8: 226-237
• 17 Overton M, Pihlsgård M, Elmståhl S. Diagnostic stability of mild cognitive impairment, and predictors of reversion to normal cognitive functioning. Dement Geriatr Cogn Dis 2020; 48: 317-329
• 18 Shimada H, Doi T, Lee S. et al. Reversible predictors of reversion from mild cognitive impairment to normal cognition: A 4-year longitudinal study. Alzheim Res Ther 2019; 11: 24
• 19 Campbell NL, Unverzagt F, LaMantia M. et al. Risk factors for the progression of mild cognitive impairment to dementia. Clin Geriatr Med 2013; 29: 873-893
• 20 Litvan I, Goldman JG, Tröster AI. et al. Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. Mov Disord 2012; 27: 349-356
• 21 McKeith IG, Ferman TJ, Thomas AJ. et al. Research criteria for the diagnosis of prodromal dementia with Lewy bodies. Neurology 2020; 94: 743-755
• 22 Gorelick PB, Scuteri AS, Black SE. et al. Vascular contributions to cognitive impairment and dementia: A statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011; 42: 2672-2713
• 23 Petersen RC, Smith GE, Waring SC. et al. Mild cognitive impairment: Clinical characterization and outcome. Arch Neurol 1999; 56: 303-308
• 24 Winblad B, Palmer K, Kivipelto M. et al. Mild cognitive impairment – Beyond controversies, towards a consensus: Report of the International Working Group on mild cognitive impairment. J Intern Med 2004; 256: 240-246
• 25 Petersen RC. Mild cognitive impairment as a diagnostic entity. J Int Med 2004; 256: 183-194
• 26 Albert MS, DeKosky ST, Dickson D. et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheim Dement 2011; 7: 270-279
• 27 American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). Washington, D.C.: American Psychiatric Association; 1994
• 28 Jack Jr CR, Scott Andrews J, Beach TG. et al. Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup. Alzheim Dement 2024; 20: 5143-5169
• 29 Dunne RA, Aarsland D, O´Brien JT. et al. Mild cognitive impairment: The Manchester consensus. Age Ageing 2021; 50: 72-80
• 30 World Health Organization (WHO). Clinical descriptions and diagnostic requirements for ICD-11 mental, behavioural and neurodevelopmental disorders. World Health Organization; 2024.
• 31 Jessen F, Amariglio RE, Buckley RF. et al. The characterisation of subjective cognitive decline. Lancet Neurol 2020; 19: 271-278
• 32 Pike KE, Cavuoto MG, Li L. et al. Subjective cognitive decline: Level of risk for future dementia and mild cognitive impairment, a meta-analysis of longitudinal studies. Neuropsychol Rev 2022; 32: 703-735
• 33 Andersen CK, Wittrup-Jensen KU, Lolk A. et al. Ability to perform activities of daily living is the main factor affecting quality of life in patients with dementia. Health Qual Life Outc 2004; 2: 1-7
• 34 Lawton MP, Brody EM. Assessment of older people: Self-maintaining and instrumental activities of daily living. Gerontologist 1969; 9: 179-186
• 35 Jekel K, Damian M, Wattmo C. et al. Mild cognitive impairment and deficits in instrumental activities of daily living: A systematic review. Alzheim Res Ther 2015; 7: 17
• 36 Schild A-K, Meiberth D, Frommann I. et al. Neuropsychologische Demenzdiagnostik: Umfrage zum klinischen Standardvorgehen im Rahmen des Deutschen Netzwerks Gedächtnisambulanzen e. V. Z Neuropsychol 2023; 34: 183-202
• 37 Erzigkeit H, Lehfeld H, Pena-Casanova J. et al. The Bayer-Activities of Daily Living Scale (B-ADL): Results from a validation study in three European countries. Dement Geriatr Cogn Disord 2001; 12: 348-358
• 38 Hindmarch I, Lehfeld H, de Jongh P. et al. The Bayer Activities of Daily Living Scale (B-ADL). Dement Geriatr Cogn Disord 1998; 9: 20-26
• 39 Lindbergh CA, Dishman RK, Miller LG. Functional disability in mild cognitive impairment: A systematic review and meta-analysis. Neuropsychol Rev 2016; 26: 129-159
• 40 Reppermund S, Birch RC, Crawford JD. et al. Performance-based assessment of instrumental activities of daily living: Validation of the Sydney Test of Activities of Daily Living in Memory Disorders (STAM). J Am Med Dir Assoc 2017; 18: 117-122
• 41 Luttenberger K, Reppermund S, Schmiedeberg-Sohn A. et al. Validation of the Erlangen Test of Activities of Daily Living in persons with mild dementia or mild cognitive impairment (ETAM). BMC Geriatr 2016; 16: 111
• 42 Bruderer-Hofstetter M, Dubbelman MA, Meichtry A. et al. Cross-cultural adaptation and validation of the Amsterdam Instrumental Activities of Daily Living questionnaire short version German for Switzerland. Health Qual Life Outc 2020; 18: 323
• 43 Jutten RJ, Peeters CFW, Leijdesdorff SMJ. et al. Detecting functional decline from normal aging to dementia: Development and validation of a short version of the Amsterdam IADL Questionnaire. Alzheim Dement 2017; 8: 26-35
• 44 Okonkwo OC, Wadley VGW, Randall Griffith H. et al. Awareness of deficits in financial abilities in patients with mild cognitive impairment: Going beyond self-informant discrepancy. Am J Geriatr Psych 2008; 16: 650-659
• 45 Rush JA, Carmody T, Reimitz PE. The inventory of depressive symptomatology (IDS): Clinician (IDS-C) and Self-Report (IDS-SR) ratings of depressive symptoms. Int J Meth Psych Res 2000; 9: 45-49
• 46 Polcher A, Wolfsgruber S, Peters O. et al. A comparison of operational definitions for mild cognitive impairment. J Alzheimers Dis 2022; 88: 1663-1678
• 47 Chandler MJ, Lacritz LH, Hynan LS. et al. A total score for the CERAD neuropsychological battery. Neurology 2005; 65: 102-106
• 48 Berres M, Monsch AU, Bernasconi F. et al. Normal ranges of neuropsychological tests for the diagnosis of Alzheimer's disease. Stud Health Technol Inform 2000; 77: 195-199
• 49 Mistridis P, Egli SC, Iverson GL. et al. Considering the base rates of low performance in cognitively healthy older adults improves the accuracy to identify neurocognitive impairment with the Consortium to Establish a Registry for Alzheimer's Disease-Neuropsychological Assessment Battery (CERAD-NAB). Eur Arch Psych Clin Neurosci 2015; 265: 407-417
• 50 Molinuevo JL, Rabin LA, Amariglio R. et al. Implementation of subjective cognitive decline criteria in research studies. Alzheim Dement 2017; 13: 296-311
• 51 Nasreddine ZS, Phillips NA, Bédirian V. et al. The Montreal Cognitive Assessment, MoCA: A brief screening tool for mild cognitive impairment. J Am Geriatr Soc 2005; 53: 695-699
• 52 Thomann AE, Goettel N, Monsch RJ. et al. The Montreal Cognitive Assessment: Normative data from a German-speaking cohort and comparison with international normative samples. J Alzheim Dis 2018; 64: 643-655
• 53 Blanken AE, Dutt S, Li Y. et al. Disentangling heterogeneity in Alzheimer's disease: Two empirically-derived subtypes. J Alzheim Dis 2019; 70: 227-239
• 54 Blanken AE, Jang JY, Ho JK. et al. Distilling heterogeneity of mild cognitive impairment in the National Alzheimer Coordinating Center database using latent profile analysis. JAMA Netw Open 2020; 3: e200413
• 55 Libon DJ, Xie SX, Eppig J. et al. The heterogeneity of mild cognitive impairment: A neuropsychological analysis. J Int Neuropsychol Soc 2010; 16: 84-93
• 56 Machulda MM, Lundt ES, Albertson SM. et al. Neuropsychological subtypes of incident mild cognitive impairment in the Mayo Clinic Study of Aging. Alzheim Dement 2019; 15: 878-887
• 57 Edmonds EC, Delano-Wood L, Clark LR. et al. Susceptibility of the conventional criteria for mild cognitive impairment to false-positive diagnostic errors. Alzheim Dement 2015; 11: 415-424
• 58 Dubois B, Padovani A, Scheltens P. et al. Timely diagnosis for Alzheimer's disease: A literature review on benefits and challenges. J Alzheim Dis 2016; 49: 617-631
• 59 Gaur A, Rivet L, Mah E. et al. Novel fluid biomarkers for mild cognitive impairment: A systematic review and meta-analysis. Ageing Res Rev 2023; 91: 102046
• 60 Liang JH, Shen W-T, Li J-Y. et al. The optimal treatment for improving cognitive function in elder people with mild cognitive impairment incorporating Bayesian network meta-analysis and systematic review. Ageing Res Rev 2019; 51: 85-96
• 61 Sherman DS, Mauser J, Nuno M. et al. The efficacy of cognitive intervention in mild cognitive impairment (MCI): A meta-analysis of outcomes on neuropsychological measures. Neuropsychol Rev 2017; 27: 440-484
• 62 Gemeinsamer Bundesausschuss. Richtlinie zu Untersuchungs- und Behandlungsmethoden der vertragsärztlichen Versorgung (Richtlinie Methoden vertragsärztliche Versorgung). Bundesanzeiger 2025; 3.
• 63 Huang X, Zhao X, Li B. et al. Comparative efficacy of various exercise interventions on cognitive function in patients with mild cognitive impairment or dementia: A systematic review and network meta-analysis. J Sport Health Sci 2022; 11: 212-223
• 64 Ahn J, Kim M. Effects of exercise therapy on global cognitive function and, depression in older adults with mild cognitive impairment: A systematic review and meta-analysis. Arch Gerontol Geriatr 2023; 106: 104855
• 65 Zhou S, Chen S, Liu X. et al. Physical activity improves cognition and activities of daily living in adults with Alzheimer's disease: A systematic review and meta-analysis of randomized controlled trials. Int J Environ Res Public Health 2022; 19: 1216
• 66 De Nys L, Anderson K, Ofosu EF. et al. The effects of physical activity on cortisol and sleep: A systematic review and meta-analysis. Psychoneuroendocrinology 2022; 143: 105843
• 67 Jessen F, Bohr L, Kruse C. et al. The German S3 guidelines on dementia. Nervenarzt 2023; 94: 609-613
• 68 Xu Z, Sun W, Zhang D. et al. Comparative effectiveness of non-pharmacological interventions for depressive symptoms in mild cognitive impairment: Systematic review with network meta-analysis. Aging Ment Health 2022; 26: 2129-2135
• 69 Wang Y, Liu M, Tan Y. et al. Effectiveness of dance-based interventions on depression for persons with MCI and dementia: A systematic review and meta-analysis. Front Psychol 2021; 12: 709208
• 70 Orgeta V, Leung P, Del-Pino-Casado R. et al. Psychological treatments for depression and anxiety in dementia and mild cognitive impairment. Coch Data Syst Rev 2022; 4: CD009125
• 71 Tonga JB, Saltyte Benth J, Arnevik EA. et al. Managing depressive symptoms in people with mild cognitive impairment and mild dementia with a multicomponent psychotherapy intervention: A randomized controlled trial. Int Psychogeriatr 2021; 33: 217-231
• 72 Cunningham EL, Todd SA, Passmore P. et al. Pharmacological treatment of hypertension in people without prior cerebrovascular disease for the prevention of cognitive impairment and dementia. Coch Data Syst Rev 2021; 5: CD004034
• 73 Yu JT, Xu W, Tan C-C. et al. Evidence-based prevention of Alzheimer's disease: Systematic review and meta-analysis of 243 observational prospective studies and 153 randomised controlled trials. J Neurol Neurosurg Psy 2020; 91: 1201-1209
• 74 Livingston G, Huntley J, Liu KY. et al. Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. Lancet 2024; 404: 572-628
• 75 Kelly AJ, Luckett T, Clayton JM. et al. Advance care planning in different settings for people with dementia: A systematic review and narrative synthesis. Palliat Support Care 2019; 17: 707-719
• 76 Brazil K, Carter G, Cardwell C. et al. Effectiveness of advance care planning with family carers in dementia nursing homes: A paired cluster randomized controlled trial. Palliat Med 2018; 32: 603-612
• 77 Bundesamt für Straßen- und Verkehrswesen. Geeignete Testverfahren und -geräte im Rahmen der Fahreignungsbegutachtung oder einer Eignungsuntersuchung nach § 11 Absatz 9 der Fahrerlaubnis-Verordnung (FeV), 31.03.2025. Zugriff am 15. Juli 2025 unter: https://www.bast.de/DE/Verkehrssicherheit/Qualitaetsbewertung/Anerkennung/u3-anerkennung/geeignete-Verfahren.html
• 78 Fastenmeier W, Gstalter H, Rompe K. et al. Selektion oder Befähigung: Wie kann die Mobilität älterer Fahrer aufrechterhalten werden? Stellungnahme namens des Vorstandes der Deutschen Gesellschaft für Verkehrspsychologie e.V. (DGVP). Z Verkehrssich 2015; 61: 33-42